BioCardia (NASDAQ:BCDA) Upgraded at Zacks Research

Posted by Geri Gentry on Aug 13th, 2026

BioCardia (NASDAQ:BCDA – Get Free Report) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Several other research analysts have also commented on BCDA. Wall Street Zen upgraded shares of BioCardia to a “sell” rating in a report on Saturday, July 18th. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of BioCardia in a research note on Tuesday, June 9th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of BioCardia in a research report on Friday, July 17th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $25.00.

View Our Latest Analysis on BCDA

BioCardia Price Performance

Shares of NASDAQ:BCDA opened at $0.88 on Tuesday. The business has a 50-day moving average of $0.94 and a two-hundred day moving average of $1.08. The firm has a market capitalization of $10.01 million, a PE ratio of -0.97 and a beta of 0.48. BioCardia has a 12 month low of $0.75 and a 12 month high of $2.29.

BioCardia (NASDAQ:BCDA – Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.05. As a group, research analysts anticipate that BioCardia will post -0.76 earnings per share for the current year.

Insider Activity at BioCardia

In related news, Director Simon H. Stertzer purchased 39,000 shares of BioCardia stock in a transaction that occurred on Tuesday, June 23rd. The shares were purchased at an average cost of $1.00 per share, with a total value of $39,000.00. Following the transaction, the director owned 166,338 shares of the company’s stock, valued at approximately $166,338. The trade was a 30.63% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In the last quarter, insiders bought 145,900 shares of company stock worth $137,212. Company insiders own 17.40% of the company’s stock.

Institutional Trading of BioCardia

Hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC boosted its stake in shares of BioCardia by 70.4% in the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after purchasing an additional 27,263 shares during the period. DRW Securities LLC acquired a new stake in BioCardia during the 4th quarter valued at $72,000. Finally, Cetera Investment Advisers purchased a new stake in BioCardia during the 2nd quarter worth $40,000. Hedge funds and other institutional investors own 20.57% of the company’s stock.

About BioCardia

(Get Free Report)

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.